journal article·2015-11

Nanoparticle delivery of CDDO-Me remodels the tumor microenvironment and enhances vaccine therapy for melanoma

Yan Zhao, Meirong Huo, Zhenghong Xu, Yuhua Wang, Leaf Huang

Biomaterials· Volume 68
Publisher page

Abstract

Lipid-calcium-phosphate nanoparticle (NP) delivery of Trp2 peptide vaccine is one of the most effective vaccine strategies against melanoma. However, due to the immunosuppressive microenvironment in the tumor, the achievement of potent immune responses remains a major challenge. NP delivery systems provide an opportunity to deliver chemotherapy agent to modulate the tumor microenvironment (TME) and improve the vaccine activity. Anti-inflammatory triterpenoid methyl-2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate (CDDO-Me) is a broad spectrum inhibitor of several signaling pathways that are important in both cancer cells and cells in the TME. Intravenous delivery of CDDO-Me using poly-lactic-glycolic-acid NP combination with subcutaneous Trp2 vaccine resulted in an increase of antitumor efficacy and apoptotic tumor tissue than Trp2 vaccine alone in B16F10 melanoma. There was a significant decrease of both Treg cells and MDSCs and a concomitant increase in the cytotoxic T-lymphocyte infiltration in TEM of the vaccinated animals. Also, CDDO-Me remodeled the tumor associated fibroblasts, collagen and vessel in TME, meanwhile, enhanced the Fas signaling pathway which could sensitize the tumor cells for cytotoxic T lymphocyte mediated killing. The combination of systemic induction of antigen-specific immune response using Trp2 nanovaccine and targeted modification of the TME with the NP delivered CDDO-Me offers a powerful combination therapy for melanoma.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Immunotherapy and Immune Responses · RNA Interference and Gene Delivery · Cancer Immunotherapy and Biomarkers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (53)

Show source-provided references
1. Combination of interleukin-12 gene therapy, metronomic cyclophosphamide and DNA cancer vaccination directs all arms of the immune system towards tumor eradication10.1016/j.jconrel.2014.05.045 ↗
2. Vaccine-elicited CD8+ T cells cure mesothelioma by overcoming tumor-induced immunosuppressive environment10.1158/0008-5472.CAN-14-0473 ↗
3. Broad-spectrum anti-tumor and anti-metastatic DNA vaccine based on p62-encoding vector10.18632/oncotarget.1397 ↗
4. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma10.1056/NEJMoa1012863 ↗
5. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine10.1200/JCO.2010.33.8053 ↗
6. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma10.1200/JCO.2013.51.4802 ↗
7. Cancer immunotherapy comes of age10.1038/nature10673 ↗
8. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps10.1038/nrc3153 ↗
9. Improving T cell responses to modified peptides in tumor vaccines10.1007/s12026-012-8348-9 ↗
10. Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy10.4161/onci.25961 ↗
11. Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis10.1016/j.jconrel.2013.08.021 ↗
12. Nanoparticle-delivered transforming growth factor-beta siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment10.1021/nn500216y ↗
13. Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis10.1038/mt.2010.34 ↗
14. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation10.1200/JCO.2009.23.3494 ↗
15. Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses10.1007/s00262-011-1020-8 ↗
16. Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer10.1097/CJI.0b013e31818fe167 ↗
17. Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease10.1124/pr.111.004846 ↗
18. Preclinical evidences toward the use of triterpenoid CDDO-Me for solid cancer prevention and treatment10.1186/1476-4598-13-30 ↗
19. Oleanane triterpenoid CDDO-Me inhibits growth and induces apoptosis in prostate cancer cells by independently targeting pro-survival Akt and mTOR10.1002/pros.20937 ↗
20. Oleanane triterpenoid CDDO-Me inhibits Akt activity without affecting PDK1 kinase or PP2A phosphatase activity in cancer cells10.1016/j.bbrc.2011.12.007 ↗
21. Identification of unique sensitizing targets for anti-inflammatory CDDO-Me in metastatic melanoma by a large-scale synthetic lethal RNAi screening10.1111/pcmr.12031 ↗
22. Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway10.1186/1471-2407-10-187 ↗
23. CDDO-Me: a novel synthetic triterpenoid for the treatment of pancreatic cancer10.3390/cancers2041779 ↗
24. ROS mediate proapoptotic and antisurvival activity of oleanane triterpenoid CDDO-Me in ovarian cancer cells
25. A synthetic triterpenoid, CDDO-Me, inhibits I kappa B alpha, kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappa B-regulated gene products in human leukemic cells10.1158/1078-0432.CCR-05-2044 ↗
26. Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer10.1158/1078-0432.CCR-09-3272 ↗
27. Targeted therapeutic remodeling of the tumor microenvironment improves an HER-2 DNA vaccine and prevents recurrence in a murine breast cancer model10.1158/0008-5472.CAN-11-1264 ↗
28. A highly efficient synthetic vector: nonhydrodynamic delivery of DNA to hepatocyte nuclei in vivo10.1021/nn4012384 ↗
29. Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor10.1016/j.jconrel.2011.10.020 ↗
30. Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy10.1016/j.biomaterials.2013.07.050 ↗
31. Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC10.1038/mt.2013.120 ↗
32. Biodistribution characteristics of galactosylated emulsions and incorporated probucol for hepatocyte-selective targeting of lipophilic drugs in mice10.1023/B:PHAM.0000029280.39882.ff ↗
33. PGE(2)-driven induction and maintenance of cancer-associated myeloid-derived suppressor cells10.3109/08820139.2012.695417 ↗
34. Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells10.4049/jimmunol.1101304 ↗
35. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis10.1158/0008-5472.CAN-05-0045 ↗
36. Glioma cancer stem cells induce immunosuppressive macrophages/microglia10.1093/neuonc/noq082 ↗
37. CD83(+) dendritic cells and Foxp3(+) regulatory T cells in primary lesions and regional lymph nodes are inversely correlated with prognosis of gastric cancer
38. Zonal difference and prognostic significance of foxp3 regulatory T cell infiltration in breast cancer10.4048/jbc.2014.17.1.8 ↗
39. Transient Foxp3(+) regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells10.1038/icb.2012.58 ↗
40. Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications10.1053/j.seminoncol.2014.02.003 ↗
41. Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma10.1158/1078-0432.CCR-14-1711 ↗
42. Listeria monocytogenes (Lm)-LLO immunotherapies reduce the immunosuppressive activity of myeloid-derived suppressor cells and regulatory T cells in the tumor microenvironment10.1097/CJI.0000000000000000 ↗
43. Chemotherapeutic targeting of cancer-induced immunosuppressive cells10.1158/0008-5472.CAN-14-0301 ↗
44. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression10.1016/j.semcancer.2012.01.011 ↗
45. The tumor microenvironment and its role in promoting tumor growth10.1038/onc.2008.271 ↗
46. Electrophilic PPARgamma ligands inhibit corneal fibroblast to myofibroblast differentiation in vitro: a potentially novel therapy for corneal scarring10.1016/j.exer.2011.11.018 ↗
47. Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation10.1021/nn5010815 ↗
48. Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model10.1016/j.jconrel.2014.03.016 ↗
49. Remodeling of tumor stroma and response to therapy10.3390/cancers4020340 ↗
50. MicroRNAs and tumor vasculature normalization: impact on anti-tumor immune response10.1007/s00005-013-0231-4 ↗
51. Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway10.1186/1479-5876-9-192 ↗
52. The Fas/Fas-ligand system: implications in the antitumor immune response and in the activity of cytotoxic agents
53. TNF-alpha and IFN-gamma are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis10.1038/jid.2012.330 ↗